Analysts predict that Molecular Templates, Inc. (NASDAQ:MTEM – Get Rating) will post ($0.43) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for Molecular Templates’ earnings. The lowest EPS estimate is ($0.54) and the highest is ($0.39). Molecular Templates reported earnings per share of ($0.28) in the same quarter last year, which suggests a negative year-over-year growth rate of 53.6%. The business is expected to report its next quarterly earnings results on Monday, January 1st.
According to Zacks, analysts expect that Molecular Templates will report full-year earnings of ($1.62) per share for the current financial year, with EPS estimates ranging from ($1.92) to ($1.33). For the next fiscal year, analysts anticipate that the company will post earnings of ($1.71) per share, with EPS estimates ranging from ($2.16) to ($1.18). Zacks Investment Research’s EPS calculations are a mean average based on a survey of research firms that follow Molecular Templates.
Molecular Templates (NASDAQ:MTEM – Get Rating) last released its earnings results on Thursday, May 12th. The biotechnology company reported ($0.38) EPS for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.04. Molecular Templates had a negative return on equity of 110.16% and a negative net margin of 177.06%. The company had revenue of $8.49 million during the quarter, compared to the consensus estimate of $6.88 million.
Shares of MTEM stock opened at $1.10 on Wednesday. Molecular Templates has a fifty-two week low of $0.88 and a fifty-two week high of $9.30. The stock has a market cap of $61.97 million, a P/E ratio of -0.80 and a beta of 1.61. The business has a fifty day simple moving average of $1.84 and a 200-day simple moving average of $2.76. The company has a quick ratio of 2.94, a current ratio of 2.94 and a debt-to-equity ratio of 0.75.
In related news, major shareholder Target N. V. Biotech acquired 200,000 shares of the company’s stock in a transaction that occurred on Monday, May 16th. The stock was purchased at an average price of $1.18 per share, for a total transaction of $236,000.00. Following the transaction, the insider now owns 11,192,003 shares in the company, valued at approximately $13,206,563.54. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 28.40% of the company’s stock.
A number of institutional investors and hedge funds have recently bought and sold shares of the business. Bellevue Group AG grew its holdings in Molecular Templates by 1.8% in the 1st quarter. Bellevue Group AG now owns 11,078,003 shares of the biotechnology company’s stock valued at $38,219,000 after buying an additional 200,000 shares during the period. BlackRock Inc. grew its holdings in Molecular Templates by 8.7% in the 4th quarter. BlackRock Inc. now owns 2,850,901 shares of the biotechnology company’s stock valued at $11,175,000 after buying an additional 228,321 shares during the period. Frazier Life Sciences Management L.P. purchased a new stake in Molecular Templates in the 1st quarter valued at about $4,740,000. Adage Capital Partners GP L.L.C. grew its holdings in Molecular Templates by 18.2% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 1,200,000 shares of the biotechnology company’s stock valued at $4,704,000 after buying an additional 185,000 shares during the period. Finally, Kingdon Capital Management L.L.C. grew its holdings in Molecular Templates by 1.0% in the 3rd quarter. Kingdon Capital Management L.L.C. now owns 1,021,317 shares of the biotechnology company’s stock valued at $6,853,000 after buying an additional 9,822 shares during the period. Institutional investors own 88.72% of the company’s stock.
Molecular Templates Company Profile (Get Rating)
Molecular Templates, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases. The company primarily develops a pipeline of therapies through its proprietary biologic engineered toxin body (ETB) drug platform.
- Get a free copy of the StockNews.com research report on Molecular Templates (MTEM)
- 3 Software Plays Showing Signs of Recovery
- It’s Time To PLAY With Dave & Buster’s
- Seagate Technology: Improved Fundamentals & Recovering Technicals
- It’s A Sweet Time To Buy The J.M. Smucker Co.
- Don’t Rush Out To Buy G-III Apparel
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Molecular Templates Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Molecular Templates and related companies with MarketBeat.com's FREE daily email newsletter.